S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:CRIS

Curis Stock Forecast, Price & News

$4.49
-0.28 (-5.87%)
(As of 12/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.46
$4.84
50-Day Range
$4.49
$8.43
52-Week Range
$1.09
$17.40
Volume
2.38 million shs
Average Volume
2.28 million shs
Market Capitalization
$411.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.83
30 days | 90 days | 365 days | Advanced Chart
Receive CRIS News and Ratings via Email

Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter.


Curis logo

About Curis

Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CRIS
CUSIP
23126910
Employees
28
Year Founded
2000

Sales & Book Value

Annual Sales
$10.84 million
Book Value
$1.12 per share

Profitability

Net Income
$-29.91 million
Net Margins
-373.25%
Pretax Margin
-373.25%

Debt

Price-To-Earnings

Miscellaneous

Free Float
87,175,000
Market Cap
$411.32 million
Optionable
Optionable

Company Calendar

Last Earnings
11/08/2021
Today
12/06/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/15/2022

Social Links


MarketRank

Overall MarketRank

1.94 out of 5 stars

Medical Sector

707th out of 1,388 stocks

Biological Products, Except Diagnostic Industry

108th out of 202 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Curis (NASDAQ:CRIS) Frequently Asked Questions

Is Curis a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Curis in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Curis stock.
View analyst ratings for Curis
or view top-rated stocks.

How has Curis' stock price been impacted by Coronavirus (COVID-19)?

Curis' stock was trading at $1.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CRIS stock has increased by 311.9% and is now trading at $4.49.
View which stocks have been most impacted by COVID-19
.

When is Curis' next earnings date?

Curis is scheduled to release its next quarterly earnings announcement on Tuesday, March 15th 2022.
View our earnings forecast for Curis
.

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) posted its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.01. Curis had a negative net margin of 373.25% and a negative trailing twelve-month return on equity of 33.62%. During the same period in the previous year, the company posted ($0.11) EPS.
View Curis' earnings history
.

When did Curis' stock split? How did Curis' stock split work?

Curis's stock reverse split before market open on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 29th 2018. An investor that had 100 shares of Curis stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for CRIS?

5 equities research analysts have issued twelve-month price objectives for Curis' shares. Their forecasts range from $15.00 to $24.00. On average, they anticipate Curis' share price to reach $19.80 in the next year. This suggests a possible upside of 341.0% from the stock's current price.
View analysts' price targets for Curis
or view top-rated stocks among Wall Street analysts.

Who are Curis' key executives?

Curis' management team includes the following people:
  • James E. Dentzer, President, Chief Executive Officer & Director
  • William E. Steinkrauss, Chief Financial Officer & Treasurer
  • Mark W. Noel, VP-Technology Management & Intellectual Property
  • Robert E. Martell, Head-Research & Development
  • Reinhard von Roemeling, Senior Vice President-Clinical Development

What other stocks do shareholders of Curis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK).

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

Who are Curis' major shareholders?

Curis' stock is owned by many different retail and institutional investors. Top institutional shareholders include Maverick Capital Ltd. (8.27%), Lord Abbett & CO. LLC (3.81%), Polar Capital Holdings Plc (3.51%), Candriam Luxembourg S.C.A. (3.30%), Emerald Advisers LLC (2.22%) and Emerald Mutual Fund Advisers Trust (2.16%).
View institutional ownership trends for Curis
.

Which institutional investors are selling Curis stock?

CRIS stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Two Sigma Investments LP, Citigroup Inc., Goldman Sachs Group Inc., Schonfeld Strategic Advisors LLC, Jane Street Group LLC, Lord Abbett & CO. LLC, and Affinity Asset Advisors LLC.
View insider buying and selling activity for Curis
or view top insider-selling stocks.

Which institutional investors are buying Curis stock?

CRIS stock was purchased by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., Polar Capital Holdings Plc, Candriam Luxembourg S.C.A., UBS Group AG, Los Angeles Capital Management LLC, Morgan Stanley, HighVista Strategies LLC, and Geode Capital Management LLC.
View insider buying and selling activity for Curis
or or view top insider-buying stocks.

How do I buy shares of Curis?

Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Curis' stock price today?

One share of CRIS stock can currently be purchased for approximately $4.49.

How much money does Curis make?

Curis has a market capitalization of $411.32 million and generates $10.84 million in revenue each year. The biotechnology company earns $-29.91 million in net income (profit) each year or ($0.46) on an earnings per share basis.

How many employees does Curis have?

Curis employs 28 workers across the globe.

When was Curis founded?

Curis was founded in 2000.

What is Curis' official website?

The official website for Curis is www.curis.com.

Where are Curis' headquarters?

How can I contact Curis?

Curis' mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at (617) 503-6500, via email at [email protected], or via fax at 617-503-6501.


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.